Breaking News

OctoPlus, Sanofi Sign Master Service Agreement

January 10, 2013

Follows ongoing formulation development pact

OctoPlus N.V. has signed a Master Service Agreement with Sanofi. This agreement follows an ongoing collaboration for the development of a number of formulations. Further details on the compound and activities are not disclosed.
Mr. Jan Egberts, chief executive officer of OctoPlus, said, "We are proud of the confidence Sanofi has shown in our organization by signing this agreement. It reflects the success of our scientists and engineers who continuously develop new formulations and formulation processes, thereby strongly adding to the value of our clients' products."

Related Contract Manufacturing:

  • U.S. Pharma Market Trends

    Kristin Brooks, Contract Pharma||April 8, 2016
    CPhI Report sees return of generic and API manufacturing to U.S. market

  • DCAT Week ’16 Session Highlights

    Kristin Brooks, Contract Pharma||March 24, 2016
    API and Dose CMO Market Trends and Supply Strategies

  • Talking Trends with Aesica

    Talking Trends with Aesica

    Tim Wright, editor||February 26, 2016
    Managing director Ian Muir fills us in on the latest at the CDMO